Literature DB >> 1567180

Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells.

A F Chambers1, E I Behrend, S M Wilson, D T Denhardt.   

Abstract

We have previously shown that transfection of NIH 3T3 cells with the T24 H-ras oncogene converts the cells to a tumorigenic and metastatic phenotype, in proportion to levels of ras expression. We hypothesize that ras-induced increases in malignancy occur via altered expression of various genes. We have identified OPN (osteopontin; also known as Secreted Phosphoprotein, 2ar, Eta-1, and transformation-associated phosphoprotein) as a ras-induced gene in these cells. We report here that expression of OPN RNA and secretion of OPN protein are increased in a series of ras-transformed NIH 3T3 cells, in proportion to levels of expression of ras. Detection of secreted OPN protein was facilitated by a barium citrate precipitation procedure. Although the function of this protein in tumor cells is not known, OPN contains a conserved GRGDS (glycine-arginine-glycine-aspartic acid-serine) amino acid sequence, which may function as a cell attachment site for this protein. We speculate that increased expression of OPN contributes to the increased malignancy of ras oncogene-transformed NIH 3T3 cells, perhaps by alterations in either adhesive properties or integrin-mediated signal transduction pathways.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1567180

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

1.  Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer.

Authors:  Guoxin Zhang; Bin He; Georg F Weber
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

Review 2.  Osteopontin: an effector and an effect of tumor metastasis.

Authors:  L A Shevde; S Das; D W Clark; R S Samant
Journal:  Curr Mol Med       Date:  2010-02       Impact factor: 2.222

3.  Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue.

Authors:  F Jahns; A Wilhelm; N Jablonowski; H Mothes; Mariya Radeva; A Wölfert; K O Greulich; M Glei
Journal:  Carcinogenesis       Date:  2011-03-31       Impact factor: 4.944

4.  Nuclear factor inducing kinase: a key regulator in osteopontin- induced MAPK/IkappaB kinase dependent NF-kappaB-mediated promatrix metalloproteinase-9 activation.

Authors:  Hema Rangaswami; Anuradha Bulbule; Gopal C Kundu
Journal:  Glycoconj J       Date:  2006-05       Impact factor: 2.916

5.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

6.  Macrophages express osteopontin during repair of myocardial necrosis.

Authors:  C E Murry; C M Giachelli; S M Schwartz; R Vracko
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

7.  Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin.

Authors:  P J Kostenuik; O Sanchez-Sweatman; F W Orr; G Singh
Journal:  Clin Exp Metastasis       Date:  1996-01       Impact factor: 5.150

8.  Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by a targeted ribozyme.

Authors:  B Feng; E E Rollo; D T Denhardt
Journal:  Clin Exp Metastasis       Date:  1995-11       Impact factor: 5.150

9.  Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines.

Authors:  V L Morris; A B Tuck; S M Wilson; D Percy; A F Chambers
Journal:  Clin Exp Metastasis       Date:  1993-01       Impact factor: 5.150

10.  Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.

Authors:  Philip C Mack; Mary W Redman; Kari Chansky; Stephen K Williamson; Nichole C Farneth; Primo N Lara; Wilbur A Franklin; Quynh-Thu Le; John J Crowley; David R Gandara
Journal:  J Clin Oncol       Date:  2008-09-08       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.